Literature DB >> 14202592

OBSERVATIONS ON THE USE OF CANCER CHEMOTHERAPEUTIC AGENTS IN PATIENTS WITH MYCOSIS FUNGOIDES.

J C WRIGHT, M M LYONS, D G WALKER, F M GOLOMB, S L GUMPORT, T J MEDREK.   

Abstract

Entities:  

Keywords:  ACTINOMYCIN; ALKYLATING AGENTS; ANTIBIOTICS; ANTINEOPLASTIC AGENTS; CARBAMATES; CHLORAMBUCIL; DRUG THERAPY; FLUOROURACIL; METHOTREXATE; MITOMYCIN; MYCOSIS FUNGOIDES; PALLIATIVE TREATMENT; SKIN NEOPLASMS; THIO-TEPA; TISSUE CULTURE; VINBLASTINE

Mesh：

Substances：

Year:  1964        PMID： 14202592     DOI： 10.1002/1097-0142(196408)17:8<1045::aid-cncr2820170811>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  5 in total

Review 1.  Methotrexate and Pralatrexate.

Authors:  Gary S Wood; Jianqiang Wu
Journal:  Dermatol Clin       Date:  2015-08-01       Impact factor: 3.478

Review 2.  Cancer chemotherapy: past, present, and future--Part I.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1984-08       Impact factor: 1.798

3.  Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome.

Authors:  Fawaz Alenezi; Céline Girard; Didier Bessis; Bernard Guillot; Aurélie Du-Thanh; Olivier Dereure
Journal:  Acta Derm Venereol       Date:  2021-02-05       Impact factor: 3.875

4.  Photopheresis therapy of cutaneous T-cell lymphoma: the Yale-New Haven Hospital experience.

Authors:  P W Heald; M I Perez; I Christensen; N Dobbs; G McKiernan; R Edelson
Journal:  Yale J Biol Med       Date:  1989 Nov-Dec

5.  Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate.

Authors:  Vassiliki Mpakou; Evangelia Papadavid; Frieda Kontsioti; Eugene Konsta; Miriam Vikentiou; Aris Spathis; Sotiris Papageorgiou; Diamantina Vasilatou; Konstantinos Gkontopoulos; Efthimia Mpazani; Petros Karakitsos; Dimitrios Rigopoulos; George Dimitriadis; Vasiliki Pappa
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.